Fredun Pharmaceuticals (539730) Q1 26/27 earnings summary

Executive summary

• Unaudited financial results for the quarter ended 30 June 2026 were reviewed and approved by the Board on 5 August 2026.

• Both standalone and consolidated results were prepared in accordance with Ind AS and reviewed by statutory auditors with unmodified conclusions.

Financial highlights

• Standalone revenue from operations for the quarter was ₹22,775.55 lakhs, up from ₹11,940.29 lakhs year-over-year.

• Standalone net profit for the quarter was ₹1,316.81 lakhs, compared to ₹676.58 lakhs in the same quarter last year.

• Consolidated revenue for the quarter was ₹22,775.55 lakhs, with consolidated net profit at ₹1,313.23 lakhs.

• Basic EPS for the quarter was ₹23.89, up from ₹14.33 year-over-year.

Outlook and guidance

• Results were reviewed and recommended by the Audit Committee and approved by the Board, indicating continued compliance and operational stability.